{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "INSM",
  "name": "Insmed Incorporated",
  "url": "https://frontierpicks.com/dossiers/INSM/",
  "json_url": "https://frontierpicks.com/dossiers/INSM.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "view_source": "research",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Insmed is more likely than not to beat the S&P 500 over three months, backed by a Bloomberg report on 19 November 2026 that Sanofi is weighing a takeover and by $400.1 million of third-quarter Brinsupri sales. The next dated test is the FDA's 28 January 2027 decision on the Arikayce label expansion.",
  "invalidation_trigger": "A daily close below $119.80, the 2026-11-18 close before the Sanofi report, which would show the takeover premium gone. An FDA rejection of the Arikayce label expansion on 2027-01-28 would also show the case failing.",
  "kill_line_kind": "price_line",
  "kill_line_due": null,
  "catalyst_date": "2027-01-28",
  "catalyst_estimated": false,
  "portfolio": null,
  "pick": null,
  "themes": [
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "Insmed is not yet profitable: its net loss was $100.3 million in the quarter to 2026-09-30, and free cash flow was negative over the four quarters to that date.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-10-29"
    }
  ],
  "source_links": [
    {
      "title": "INSMED Inc - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500_ex99-1.htm",
      "date": "2026-10-29"
    },
    {
      "title": "Sanofi weighs takeover of US drugmaker Insmed, Bloomberg News reports",
      "url": "https://malaysia.news.yahoo.com/sanofi-weighs-takeover-us-drugmaker-152042942.html",
      "date": "2026-11-19"
    },
    {
      "title": "Sanofi Considers Buying Insmed as Pharma Giants Seek New Drug Portfolios",
      "url": "https://www.bloomberg.com/news/articles/2026-11-19/sanofi-weighs-takeover-of-us-drugmaker-insmed",
      "date": "2026-11-19"
    },
    {
      "title": "INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance",
      "url": "https://www.zacks.com/stock/news/3019743/insm-q3-earnings-miss,-stock-soars-on-sales-beat-&-raised-guidance-",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 revenue was $524.4 million, up 268% from $142.3 million a year earlier. Brinsupri contributed $400.1 million and Arikayce $124.4 million.",
      "source": "Insmed 8-K, exhibit 99.1, 2026-10-29",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Insmed raised its 2026 Brinsupri revenue guidance to $1.35–1.4 billion, from $1.25–1.4 billion. It raised Arikayce guidance to $460–470 million, from $450–470 million.",
      "source": "Insmed 8-K, exhibit 99.1, 2026-10-29",
      "as_of": "2026-10-29"
    },
    {
      "claim": "The FDA accepted the Arikayce supplemental application for all MAC lung disease patients under Priority Review, with a decision date of 2027-01-28.",
      "source": "Insmed 8-K, exhibit 99.1, 2026-10-29",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Bloomberg reported that Sanofi is weighing a takeover of Insmed and speaking with advisers. Neither company immediately commented to Reuters.",
      "source": "Reuters via Yahoo News, 2026-11-19",
      "as_of": "2026-11-19"
    },
    {
      "claim": "The third-quarter 2026 net loss was $100.3 million, or $0.46 a share. The Zacks consensus loss was $0.34 a share.",
      "source": "Zacks, 2026-10-29; Insmed 8-K, 2026-10-29",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Cash and short-term investments were $1,147 million against $547 million of long-term debt at 2026-09-30.",
      "source": "Insmed 10-Q for the third quarter of 2026",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Director David R. Brennan sold 25,000 shares in the open market at $124.00 on 2026-09-09.",
      "source": "SEC Form 4 filed 2026-09-11",
      "as_of": "2026-09-09"
    },
    {
      "claim": "Brinsupri was approved in Japan in August 2026 for non-cystic fibrosis bronchiectasis and launched there in October 2026.",
      "source": "Insmed 8-K, exhibit 99.1, 2026-10-29",
      "as_of": "2026-10-29"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-20",
    "business": "Insmed sells two drugs for serious lung diseases. Brinsupri treats non-cystic fibrosis bronchiectasis. Arikayce treats MAC lung infection. Both are sold in the US, Europe and Japan. Revenue was $524.4 million in the quarter to 2026-09-30, of which Brinsupri brought in $400.1 million.",
    "change": {
      "now": "On 2026-11-19 Bloomberg reported that Sanofi is weighing a takeover of Insmed and speaking with advisers. The shares closed at $144.46, up from $119.80 the session before.",
      "next": "Brinsupri sales lifted gross margin to 85.1% and cut the operating loss to $89.4 million in the third quarter of 2026. Research spending of $270.0 million still kept four-quarter free cash flow at −$628 million.",
      "linked": "A bid would give Sanofi (SNY) a respiratory drug launch as Dupixent patents near expiry, and Bloomberg said other suitors could emerge. TPIP targets markets United Therapeutics (UTHR) serves with Tyvaso."
    },
    "priced_in": "At the 2026-11-19 close (filed inputs to 2026-10-29) the shares trade at 20.5 times sales and 43.6 times book value, for an enterprise value of $31,092 million. EV/EBIT and P/E are not meaningful because the company still loses money. That holds only if revenue keeps compounding from the latest quarter's $524 million while the −17.0% operating margin turns positive.",
    "priced_in_filed": null,
    "links": {
      "customers": [],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "UTHR",
          "url": null
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-20",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-20",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-29",
              "restated": null,
              "value_musd": 524.4,
              "yoy_pct": 268.4
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "value_musd": 425.5,
              "yoy_pct": 296.1
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "value_musd": 306,
              "yoy_pct": 229.6
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-19",
              "restated": null,
              "value_musd": 263.8,
              "yoy_pct": 152.6
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-30",
              "restated": null,
              "value_musd": 142.3,
              "yoy_pct": 52.4
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "value_musd": 107.4,
              "yoy_pct": 18.9
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-29",
              "restated": null,
              "pct": 85.1
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "pct": 84.2
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "pct": 84.5
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-19",
              "restated": null,
              "pct": 83.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-30",
              "restated": null,
              "pct": 79.4
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "pct": 73.9
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-29",
              "restated": null,
              "pct": -17
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-06",
              "restated": null,
              "pct": -0.4
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-07",
              "restated": null,
              "pct": -50.1
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-19",
              "restated": null,
              "pct": -121.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-30",
              "restated": null,
              "pct": -257.1
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-07",
              "restated": null,
              "pct": -291.3
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": -97.7
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "four_quarters_end": "2026-09-30",
          "value_musd": -100.3,
          "four_quarters_musd": -605.6
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "first_end": "2025-12-31",
          "value_musd": -595.6
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "first_end": "2025-12-31",
          "value_musd": 32
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "first_end": "2025-12-31",
          "value_musd": -627.6
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "base_end": "2025-09-30",
          "pct": 3.3
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": 1146.6
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": 546.8,
          "composition": "long-term debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": 599.9
        },
        "deferred_revenue": {
          "status": "not reported"
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": 259.3
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": 163.9
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-29",
          "value_musd": 726.2
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-23",
          "basis_filed": "2026-10-29",
          "value_musd": 31005
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-23",
          "basis_filed": "2026-10-29",
          "value_musd": 30405.2
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-23",
          "basis_filed": "2026-10-29",
          "multiple": 20
        },
        "ev_ebit": {
          "status": "not meaningful"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-23",
          "basis_filed": "2026-10-29",
          "multiple": 42.7
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-10-23",
          "basis_filed": "2026-10-29",
          "pct": -2
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 6.42,
      "days_to_cover": 3.6,
      "change_pct": 4.5
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\nInsmed's shares are more likely than not to beat the S&P 500 over the next three months. Two things support that view. Bloomberg reported on 2026-11-19 that Sanofi is weighing a takeover. Separately, the company's lung-disease drug Brinsupri sold $400.1 million in its third full quarter on the market. The Food and Drug Administration (FDA) decision on the Arikayce label expansion, due 2027-01-28, is the next dated test. Whether Sanofi makes a bid is the other.\n\nThe rating is Medium. The takeover report puts a floor of interest under the shares, and the launch numbers give a buyer a reason to pay. It is not High because no offer exists. Reuters reported on 2026-11-19 that neither company commented and that any deal \"could still be weeks away.\" Without a bid, the gain from the report can unwind.\n\n## Bull Case\n- **Brinsupri launch is ahead of plan.** Brinsupri revenue was $400.1 million in the quarter to 2026-09-30, up 29% from $309.2 million in the previous quarter. Total revenue was $524.4 million, up 268% from a year earlier (company 8-K, 2026-10-29).\n- **Guidance floor moved up.** On 2026-10-29 the company raised the low end of its 2026 Brinsupri revenue guidance to $1.35–1.4 billion, from $1.25–1.4 billion. It raised Arikayce guidance to $460–470 million, from $450–470 million.\n- **A strategic buyer is circling.** Bloomberg reported on 2026-11-19 that Sanofi is speaking with advisers about a takeover. The same report said other suitors could emerge. Sanofi's chief executive has called business development \"critical\" ahead of Dupixent patent expiries in the early 2030s.\n- **Margins are moving the right way.** Gross margin rose to 85.1% in the quarter to 2026-09-30, from 79.4% a year earlier. The operating margin improved to −17.0%, from −257.1% (10-Q filed 2026-10-29).\n- **A near-term regulatory event.** The FDA accepted the Arikayce supplemental application for all patients with MAC lung disease under Priority Review. The decision date is 2027-01-28 (company 8-K, 2026-10-29). MAC is Mycobacterium avium complex, a hard-to-treat lung infection.\n\n## Bear Case\n- **The premium rests on an unconfirmed report.** The 2026-11-19 move came from a Bloomberg report citing people familiar with the matter. Neither company commented to Reuters that day. If Sanofi steps back, the report-day gain could unwind.\n- **Still losing money and burning cash.** The net loss was $100.3 million in the quarter to 2026-09-30. Free cash flow was −$628 million over the four quarters to that date. Cash and short-term investments were $1,147 million against $547 million of long-term debt (10-Q filed 2026-10-29).\n- **Heavy spending on the next drug.** Research and development expense rose to $270.0 million in the third quarter of 2026, from $186.4 million a year earlier. The pipeline includes three TPIP Phase 3 programs. PALM-ILD enrollment is not expected to finish until the first half of 2028 (company 8-K, 2026-10-29).\n- **Earnings missed the consensus.** The third-quarter 2026 loss of $0.46 a share was wider than the Zacks consensus loss of $0.34 (Zacks, 2026-10-29).\n- **A director sold before the rally.** Director David R. Brennan sold 25,000 shares in the open market at $124.00 on 2026-09-09 (SEC Form 4, filed 2026-09-11).\n\n## Setup & Price Structure\nThe shares closed at $144.46 on 2026-11-19, up from $119.80 on 2026-11-18, on the day of the Sanofi report. The price had held between $118.07 and $122.88 from 2026-11-12 to 2026-11-18. The 2026-11-19 close is above the 50-day moving average of $110.86 and the 200-day moving average of $122.61, both as of that close.\n\nThe 3-month price change is 14.9%, against a reference close of $125.77 on 2026-08-21. The shares are still 32.1% below the 52-week intraday high of $212.75, set on 2025-12-02. The 52-week closing low was $91.88 on 2026-06-10. The pre-report closes from $118 to $123 mark where the price traded before takeover interest became public. A return to that range would mean the market no longer expects a bid.\n\nAcross liquid US stocks, no reliable effect has been found so far for what a one-day jump of this size means for the following 21 or 63 sessions.\n\n## Catalyst Calendar\n\n- **2027-01-28:** FDA decision date on the Arikayce supplemental application for all MAC lung disease patients. Approval would widen Arikayce's US market and support the case. A rejection would weaken both the drug's growth and a buyer's valuation.\n- **~2027-02-19 (est.):** Fourth-quarter and full-year 2026 results. Shows whether full-year Brinsupri revenue lands within the $1.35–1.4 billion guidance, and whether the operating loss keeps narrowing.\n\n## What Would Change Our Mind\n\nA daily close below $119.80, the 2026-11-18 close before the Sanofi report, which would show the takeover premium gone. An FDA rejection of the Arikayce label expansion on 2027-01-28 would also show the case failing.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Sanofi decides not to bid and the takeover premium leaves the shares. Confirmed by: A statement from Sanofi or Insmed, or a follow-up report from Bloomberg or Reuters, saying talks have ended or that no approach is under way.\n- Brinsupri growth slows as the launch matures. Confirmed by: Fourth-quarter 2026 Brinsupri revenue that puts the full year below the $1.35 billion low end of guidance.\n- The FDA does not approve the wider Arikayce label. Confirmed by: A complete response letter, or a delay announced on or before the 2027-01-28 decision date.\n- Cash burn forces new share sales, diluting holders. Confirmed by: An equity or convertible offering. Diluted shares were already up 3.3% from a year earlier in the quarter to 2026-09-30.\n\n## Correlation Notes\nFor now the shares are trading on the deal. Their next big move depends on news from Sanofi (SNY), or a denial, more than on the biotech group. Brinsupri sales and the FDA decision on 2027-01-28 drive the company-specific path.\n\nTPIP, Insmed's inhaled treprostinil, is aimed at markets United Therapeutics (UTHR) serves with Tyvaso. Trial news in pulmonary hypertension moves both names. Single stocks vary widely: the standard deviation of 63-session returns across liquid US stocks was 27% in 2026, so a three-month result for one name is a noisy reading.",
  "first_seen": "2026-11-19",
  "last_analyzed": "2026-11-20T03:33:38+00:00",
  "last_synthesized": "2026-11-20",
  "date_modified": "2026-11-20",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}